June 2012 Volume 8, Issue 6

Volume 8, Issue 6 | June 2012

June 2012

In this Issue

Contract Services

Drug Discovery News Placeholder Image

Raising the third pillar

Synexus strengthens its presence in Poland with acquisition of Osteomed to complement German and U.K. presence
Drug Discovery News Placeholder Image

Spain and France join hands

Harlan Labs partners with Ipsen for development of preclinical drug candidates
Drug Discovery News Placeholder Image

Partnering for Phase III

Amgen selects PRA as CRO of choice for Phase III biosimilars trials
Drug Discovery News Placeholder Image

Hustling on half-lives

Caisson Biotech licenses heparosan-based delivery technology to Novo Nordisk to extend half-lives on drugs
Drug Discovery News Placeholder Image

AMRI inks deal with Biota Holdings

AMRI was recently selected by Biota Holdings Ltd. to further develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor

Diagnostics

Drug Discovery News Placeholder Image

Childhood cancer collaboration

Penn State Hershey Children’s Hospital and Serametrix to develop Dx test for pediatric cancers
Drug Discovery News Placeholder Image

The way to man’s heart— through his stomach

LipoScience will translate Cleveland Clinic research into cardiovascular test based on gut flora metabolite
Drug Discovery News Placeholder Image

A hankering for HER2

Dako, Genentech pair up for FDA submissions of HER2 companion diagnostics
Drug Discovery News Placeholder Image

NGS for cancer Dx

Genomic Health and OncoMed use next-generation sequencing to develop personalized cancer therapeutics
Drug Discovery News Placeholder Image

QIAGEN joins POC Dx Initiative

QIAGEN announced May 3 that it has joined the Point-of-Care Diagnostics (POC Dx) Initiative led by the Bill & Melinda Gates Foundation and Grand Challenges Canada
Drug Discovery News Placeholder Image

Stretching its wings

Hologic acquires Gen-Probe for a total enterprise value of approximately $3.7 billion

Global News

Drug Discovery News Placeholder Image

Turning toward Turkey

Amgen to acquire Mustafa Nevzat Pharmaceuticals, increase international presence
Drug Discovery News Placeholder Image

Australian pharma nabs U.S. shareholders

Biota, Nabi Biopharmaceuticals to merge in $212 million deal
Drug Discovery News Placeholder Image

A duo that’s sweet on new biomarkers

Ezose Sciences and Hirosaki University to collaborate in glycomics research to find new cancer biomarkers
Drug Discovery News Placeholder Image

A joint research project

Novo Nordisk, Oxford University forge arthritis drug development deal
Drug Discovery News Placeholder Image

Evotec licenses inflammatory disease compounds to Chinese pharma

Evotec AG announced the grant of a development and marketing license to Conba Pharmaceutical Co. Ltd. of China
Drug Discovery News Placeholder Image

Sandoz acquires Fougera Pharmaceuticals

$1.5 billion deal makes Novartis group the top global generic dermatology medicines company

Research & Development

Drug Discovery News Placeholder Image

Watson adds action and strength to generics position

Pharma acquires privately held generic drugmaker Actavis Group for $5.4 billion
Drug Discovery News Placeholder Image

Out with gout

AstraZeneca acquires Ardea Biosciences for $1.26 billion, gains gout program
Drug Discovery News Placeholder Image

Right on TARGET

Merck, Endocyte reach deal to develop cancer drug
Drug Discovery News Placeholder Image

Long court battle over stem cell research continues

Three-judge panel hears oral arguments in Sherley case
Drug Discovery News Placeholder Image

NCATS finds new tricks for old dogs

NIH launches industry-government collaboration with Big Pharma to repurpose clinical-stage drugs
Drug Discovery News Placeholder Image

Accelerated development

AstraZeneca, Axerion team up to take biologic approach to treating Alzheimer’s disease
Drug Discovery News Placeholder Image

Sanofi collaborates with MJFF on Parkinson’s disease treatment

Sanofi announced in late April that it has entered into a collaboration with the Michael J. Fox Foundation (MJFF) to conduct a clinical trial to assess the safety and tolerability of AVE 8112, a Sanofi phosphodiesterase type 4 (PDE4) inhibitor, in patients with Parkinson’s disease

Commentary

Drug Discovery News Placeholder Image

Release of proposed AMP rule creates new issues for life-science industry

The new guidelines will have a wide-reaching financial impact on the life- science industry by creating serious administrative and operational challenges that will have to be addressed relatively quickly.
Drug Discovery News Placeholder Image

Making decisions … and making them work

How do we make decisions? Do we analyze Democrats and Republicans with respect to their overall “comparative effectiveness,” or is it their “comparative ineffectiveness” that influences our thinking?

Editor's Focus

Drug Discovery News Placeholder Image

Michael J. Fox drives stem cell research efforts for Parkinson’s disease back to the future

He’s not climbing into his DeLorean and punching in a destination far into the past, but actor and Parkinson’s disease advocate Michael J. Fox surprised many recently when he told ABC News reporter Diane Sawyer that stem cell research may not be the future of treatments or a cure for this debilitating disease.

Tools & Technology

Drug Discovery News Placeholder Image

Companies create ‘road atlas’ of human biology

BioTime acquires XenneX to map stem cell types
Drug Discovery News Placeholder Image

‘Mainlining’ research content to scientists

Thomson Reuters and IDBS integration aims to change biological content delivery
Drug Discovery News Placeholder Image

Getting everyone’s heads in the cloud

BT advances cloud services to increase pharmaceutical R&D productivity and optimize clinical trial results
Drug Discovery News Placeholder Image

Dolomite joins forces with LioniX

Companies partner on development of microfluidic devices and systems
Drug Discovery News Placeholder Image

Ambry Genetics launches Fluidigm-based genomic research services

Ambry Genetics, a global leader in clinical diagnostics and genomic services, announced last month the launch of Fluidigm BioMark HD and Access Array System-based genomic research services

Omics & Systems Biology

Drug Discovery News Placeholder Image

New class is in session

GSK teams up with Yale to design a new class of medicines to attack disease-causing proteins
Drug Discovery News Placeholder Image

Creating a new oral tradition

Boosted by NIH grant, NYU-UCSF research team will use genomics to find biomarkers to predict oral cancer metastasis in patients
Drug Discovery News Placeholder Image

Fresh horizons in drug discovery

Horizon, H3 Biomedicine announce target validation collaboration
Drug Discovery News Placeholder Image

Two down, 94 to go

Epizyme and Celgene partner to advance human health through epigenetic-based therapies
Drug Discovery News Placeholder Image

BGI and several academic partners to sequence 100 human adenoviruses

BGI announced May 2 that the genomics organization will work with George Mason University (GMU), the Massachusetts Eye and Ear Infirmary and the University of Oklahoma Health Sciences Center (OUHSC) to sequence 100 human adenoviruses gathered from researchers globally, including ones that cause respiratory, gastrointestinal and ocular diseases
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue